<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">

	<title type="text">News</title>
	<subtitle type="text">News:</subtitle>
	<link rel="alternate" type="text/html" href="/news" />
	<link rel="self" type="application/atom+xml" href="http://www.emeraldbiostructures.com/" />
	<updated>2013-04-08T09:54:02Z</updated>
	<rights>Copyright (c) 2013, Tina Beauchemin</rights>
	<generator uri="http://expressionengine.com/" version="2.2.1">ExpressionEngine</generator>
	<id>tag:,2013:04:02</id>


	<entry>
	  <title>Emerald Bio Makes Imagination the Only Limit to Protein Purification</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/emerald_bio_makes_imagination_the_only_limit_to_protein_purification" />
	  <id>tag:,2013:/news/1.647</id>
	  <published>2013-04-02T20:47:00Z</published>
	  <updated>2013-04-08T09:54:02Z</updated>
	  <author>
			<name>Tina Beauchemin</name>
			<email>tbeauchemin@embios.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
			<div class="news_image">
				<img src="http://www.emeraldbiostructures.com/images/blog/manual_control_tab.png" alt="" />
				<p class="caption"></p>
			</div>
			
		<p>
	Emerald Bio, the protein resource, provides biochemists and other scientists new power and freedom to create unlimited types of protein purification methods for drug discovery using its new ProteinMaker&trade; 2.0 software. The new software is a free, downloadable upgrade for existing users with a service contract. It is installed in all new ProteinMaker&trade; instruments.</p>
<p>
	&ldquo;Customers now have full control over all hardware components, so they can either follow our successful pre-loaded protocols, or easily set up their own with an unlimited number of steps,&rdquo; said Laura Sailor, Emerald Bio&rsquo;s vice president of marketing and sales. &ldquo;Imagination is their limitation.&rdquo;</p>
<p>
	Emerald Bio&rsquo;s latest ProteinMaker&trade; software has a simulation mode that lets researchers invent, test, edit and archive new protein purification methods. In addition, the software upgrade includes Emerald Bio&rsquo;s innovative methods library. Besides enabling full control over the instrument&rsquo;s syringe pumps, valves and robotic XYZ gantry, the new software upgrade gives scientists the ability to pause any process whenever they want. The instrument easily adapts to a user&rsquo;s unique needs.</p>
<p>
	<a href="/images/uploads/ProteinMaker_SW_news_release_4_2_2013.pdf">Read the full release</a></p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>Space station to aid Bedford firm’s drug research</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/space_station_to_aid_bedford_firms_drug_research" />
	  <id>tag:,2013:/news/1.646</id>
	  <published>2013-03-26T16:37:06Z</published>
	  <updated>2013-03-26T11:44:08Z</updated>
	  <author>
			<name>Tina Beauchemin</name>
			<email>tbeauchemin@embios.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
			<div class="news_image">
				<img src="http://www.emeraldbiostructures.com/images/blog/nasa.jpg" alt="A NASA image shows the SpaceX capsule Dragon being snagged by an arm of the International Space Station this month." />
				<p class="caption">A NASA image shows the SpaceX capsule Dragon being snagged by an arm of the International Space Station this month.</p>
			</div>
			
		<p>
	From <a href="http://www.bostonglobe.com">http://www.bostonglobe.com</a> on March 25, 2013:</p>
<p>
	A Bedford biotech company is going a long way in the search for lifesaving drugs: 240 miles straight up.</p>
<p>
	Emerald BioSystems Inc. is part of team of researchers using the low-gravity atmosphere of the International Space Station to develop&shy; a more complete understanding of the intricate structure of proteins, which in turn would give drug makers more insight into treating diseases.</p>
<p>
	&ldquo;Name a disease, and a protein is involved,&rdquo; said Cory Gerdts, Emerald Bio&rsquo;s instrument systems&shy; product manager. To create new drugs, &ldquo;you have to understand what the proteins involved&shy; in causing that disease or curing that disease are doing.&rdquo;</p>
<p>
	The experiment involves turning proteins into crystals, which allows scientists to make extremely&shy; detailed three-dimensional images of a protein&rsquo;s structure.</p>
<p>
	<a href="http://www.bostonglobe.com/business/2013/03/24/space-final-frontier-for-drug-makers/xyUzCQSbRjkropEjCD9tEI/story.html?s_campaign=8315">More</a><br />
	&nbsp;</p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>Growing Proteins, 240 Miles Above Earth</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/growing_proteins_240_miles_above_earth" />
	  <id>tag:,2013:/news/1.644</id>
	  <published>2013-03-19T20:52:17Z</published>
	  <updated>2013-03-19T16:01:21Z</updated>
	  <author>
			<name>Tina Beauchemin</name>
			<email>tbeauchemin@embios.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
		<p>
	<strong>From </strong><em><strong>Genetic Engineering &amp; Biotechnology News </strong></em><strong>-<em><strong> </strong></em>March 14, 2013</strong></p>
<p>
	A series of experiments on board the International Space Station (ISS) is expected to shed light on whether protein crystals grown in microgravity can offer insights that will someday help researchers on earth in developing new drugs.</p>
<p>
	Using microfluidic protein crystallization technology developed by Emerald Bio, two researchers set up some 5,000 crystallization experiments set to unfold within the ISS, now orbiting 240 miles above the earth. The experiments are designed to yield new knowledge about the structure and function of the proteins, though the research has not focused on a particular target or drug.</p>
<p>
	&ldquo;The idea is to have a platform by which any investigator working on disease X or Y can have more way to try to get that little bit more of resolution in their protein structure that they need, to get the information they need to go the next step down the road in their drug discovery or research effort,&rdquo; Cory J. Gerdts, Ph.D., instrument systems product manager with Emerald Bio, told GEN.</p>
<p>
	<a href="http://www.genengnews.com/gen-news-highlights/growing-proteins-240-miles-above-earth/81248101/"><em>Read the complete article</em></a></p>
<p>
	&nbsp;</p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>Emerald Bio and NanoRacks Test Space&#8217;s Microgravity as a New Lab for Drug Discovery</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/emerald_bio_and_nanoracks_test_spaces_microgravity_as_a_new_lab_for_drug_di" />
	  <id>tag:,2013:/news/1.642</id>
	  <published>2013-03-13T16:15:09Z</published>
	  <updated>2013-03-13T16:28:11Z</updated>
	  <author>
			<name>Tina Beauchemin</name>
			<email>tbeauchemin@embios.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
			<div class="news_image">
				<img src="http://www.emeraldbiostructures.com/images/blog/Spacecarft_Dragon.jpg" alt="Spacecraft Dragon carrying Emerald Bio's CrystalCards rockets into space.

Image by Craig Bailey, Florida Today" />
				<p class="caption">Spacecraft Dragon carrying Emerald Bio's CrystalCards rockets into space.

Image by Craig Bailey, Florida Today</p>
			</div>
			
		<p>
	The frontier of biomedical research is in a low orbit above the Earth this month. Emerald Bio scientist Cory Gerdts, Ph.D. and The Methodist Hospital Research Institute biochemist Carl Carruthers on behalf of NanoRacks, LLC are trying to learn if protein crystals grown in microgravity will help researchers on Earth create drugs that better fight diseases.</p>
<p>
	Twenty-five of Emerald Bio&rsquo;s CrystalCards containing more than 5,000 protein crystallization experiments were among more than a ton of research materials and other supplies ferried to the International Space Station March 1st by the commercial spacecraft Dragon operated by SpaceX.</p>
<p>
	A problem threatened the flight only nine minutes after its liftoff from Cape Canaveral Air Force Station in Florida. Pressurized helium lines to its three of its four thrusters became clogged. Once unjammed, the unmanned Falcon 9 rocket safely reached the space station 240 miles above Earth Sunday, March 3, 2013.</p>
<p>
	Leading protein resource Emerald Bio, headquartered in Bedford, Massachusetts was selected and financed by NanoRacks of Houston, Texas to make the space station&rsquo;s unique microgravity environment available to crystallography researchers. Since 2009, NanoRacks has offered scientists commercial opportunities to use the U.S. National Lab on space station for education and industry research. Its current signed customer pipeline of more than 80 payloads including domestic and international educational institutions, research organizations and government organizations, has propelled NanoRacks into a leadership position in understanding the emerging commercial market for low&#8208;earth orbit experiments.</p>
<p>
	At Emerald Bio&rsquo;s Bainbridge Island (Seattle) laboratory before liftoff, Carruthers, who also writes the Houston Chronicle blog Protein Wrangler and Gerdts, Emerald Bio&rsquo;s instrument systems product manager, used the Emerald Bio&rsquo;s microfluidic protein crystallization technology to set up an estimated 5,000 crystallization experiments. The CrystalCards were filled using Emerald Bio&rsquo;s Plug Maker&trade; instrument and then they were flash frozen in liquid nitrogen (between -196C and -210C) to halt protein crystal nucleation.</p>
<p>
	&ldquo;Working in microgravity to set up experiments is difficult,&rdquo; Gerdts said. &ldquo;The process of setting up experiments on CrystalCards in advance and flash freezing them reduces the risk of experiments failing and lets us try thousands more crystal-growing experiments in space than ever before.&rdquo;</p>
<p>
	Growing protein crystals to learn the intricacies of their structure and function is an early step toward creating new drugs that can improve human health.</p>
<p>
	&ldquo;We selected Emerald Bio precisely because their hardware and procedures are industry standards,&rdquo; said Michael Johnson, NanoRacks&rsquo; chief technology officer. &ldquo;It&rsquo;s time to move beyond space-unique hardware where possible.&rdquo;</p>
<p>
	On the space station, astronauts will place the Emerald Bio CrystalCards in NanoRacks&rsquo; Crystal-NanoLab to thaw so their nucleation and crystallization behavior resumes in microgravity. Once thawed, these CrystalCards will be maintained at 24 C, the ambient temperature of the space station. During the two-month mission, astronauts will twice record still and moving images of protein crystallization using off-the-shelf, digital, universal serial bus (USB) microscope provided by NanoRacks. The images will be transmitted directly to NanoRacks and shared with Carruthers and Gerdts for review. While low resolution, the microscope offers sufficient image clarity to determine if crystal growth is present. Another 25 matching CrystalCards with an estimated 5,000 experiments remain on Earth as controls.</p>
<p>
	&ldquo;We&rsquo;re trying to determine if better quality protein crystals can be grown in the absence of gravity than on earth,&rdquo; Gerdts said. &ldquo;Microgravity of the space station offers us an unadulterated situation that may improve the quality of protein crystals, which in turn we hope pushes the frontier of drug discovery.&rdquo;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p>
	Emerald Bio&rsquo;s CrystalCards are optimized for success because they allow researchers to vary the concentrations and percentages of a protein, the buffer and the precipitate for the growth of a single protein on a single card. Each card requires only 4uL of one protein, and can accommodate from 400 to 800 variations of crystal growth conditions.</p>
<p>
	While Spacecraft Dragon is scheduled to return to Earth March 25, returning investigation samples are currently scheduled to return to Russia on Soyuz TMA-07M in May. Once landed, Emerald Bio&rsquo;s CrystalCards will be returned to NanoRacks in about 24 hours. Determining the results of the experiments will take several months.</p>
<p>
	&ldquo;Crystals have been grown in space before but never on this scale,&rdquo; Gerdts said. &ldquo;Our goal is to demonstrate the feasibility of biomedical research in microgravity and offer the drug-discovery community the opportunity to participate in advancing medicine in space.&rdquo;&nbsp;</p>
<p>
	NanoRacks plans to offer crystallography researchers that opportunity again when SpaceX 4 lifts off in April 2014. NanoRacks will be working with the Center for the Advancement of Science (CASIS) and Emerald Bio to alert government and industry researchers to this n<img src="/images/uploads/Carl_Carruthers_Cory_Gerdts.jpg" style="width: 245px; height: 145px; float: left; margin: 5px;" />ew opportunity.</p>
<p>
	&nbsp;</p>
<p>
	<em>Biochemist Carl Carruthers on behalf of NanoRacks and Cory Gerdts, Ph.D., Emerald Bio&rsquo;s instrument systems product manager, (right) preparing CrystalCards for space</em></p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>Emerald Bio to Highlight Strategies for  Accelerating Drug Discovery and Reducing Risk at  Biophysical Society’s Annual Meeting</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/emerald_bio_to_highlight_strategies_for_accelerating_drug_discovery_and_red" />
	  <id>tag:,2013:/news/1.636</id>
	  <published>2013-01-30T19:39:26Z</published>
	  <updated>2013-01-30T15:58:27Z</updated>
	  <author>
			<name>Tina Beauchemin</name>
			<email>tbeauchemin@embios.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
		<p>
	Leading protein resource Emerald Bio will highlight its capabilities for accelerating drug discovery and reducing risks during the Biophysical Society&rsquo;s 57th annual meeting Feb. 2 to 6 at the Pennsylvania Convention Center in Philadelphia, Booth 818.</p>
<p>
	Darren Begley, Ph.D., leads Emerald Bio&rsquo;s biophysics core laboratory, and as part of the team will provide insights into nuclear magnetic resonance (NMR) spectroscopy, fragment-based drug lead discovery and development, protein expression, protein purification, and X-ray crystallography.</p>
<p>
	<a href="/images/uploads/Biophysical_Society_Meeting_01_31.pdf">Read more</a></p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>Emerald Bio Showcases Improvements in Protein Purification  Efficiency and Effectiveness at PepTalk 2013</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/emerald_bio_showcases_improvements_in_protein_purification_efficiency_and_e" />
	  <id>tag:,2013:/news/1.632</id>
	  <published>2013-01-21T21:35:27Z</published>
	  <updated>2013-01-30T15:57:29Z</updated>
	  <author>
			<name>Tina Beauchemin</name>
			<email>tbeauchemin@embios.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
		<p>
	Emerald Bio, the leading protein resource, will showcase top techniques and tools addressing the drug-discovery industry&rsquo;s challenge of improving the efficiency and effectiveness of protein purification during Cambridge Healthtech Institute&rsquo;s 12th annual PepTalk Jan. 21 to 25 at the Palm Springs Convention Center, Palm Springs, California at Booth 124.</p>
<p>
	<a href="/images/uploads/PepTalk_01_13.pdf">Read the news release here</a></p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>BioBlocks and Emerald Bio Align to Speed and Streamline Discovery of Small&#45;Molecule Drugs</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/bioblocks_and_emerald_bio_align_to_speed_and_streamline_discovery_of_small" />
	  <id>tag:,2013:/news/1.631</id>
	  <published>2013-01-08T13:20:34Z</published>
	  <updated>2013-01-08T08:01:36Z</updated>
	  <author>
			<name>Tina Beauchemin</name>
			<email>tbeauchemin@embios.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
			<div class="news_image">
				<img src="" alt="" />
				<p class="caption"></p>
			</div>
			
		<p>
	BioBlocks, Inc., an emerging leader in fragment-based lead discovery, and Emerald Bio, a protein and structural biology service provider, are working together to streamline clients&rsquo; access to expertise that will accelerate lead discovery and generate high-quality, small-molecule drugs in a cost effective manner.</p>
<p>
	BioBlocks&rsquo; Leap-to-Lead&trade; platform joined with Emerald Bio&rsquo;s biophysical screening and structural biology capabilities, which use co-crystallization, nuclear magnetic resonance and other methodologies, provides clients with extensive, fully integrated, fragment-based, target-to-lead generation services.</p>
<p>
	<a href="/images/uploads/BioBlocks_and_Emerald_Bio_1-8-13_final.pdf">Read the full release here</a></p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>Emerald Bio, the Science and Technology Facilities Council and the University of Oxford announce a partnership for PiMS™ Commercial Software</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/emerald_bio_the_science_and_technology_facilities_council_and_the_universit" />
	  <id>tag:,2012:/news/1.628</id>
	  <published>2012-11-27T18:51:58Z</published>
	  <updated>2013-01-08T08:03:00Z</updated>
	  <author>
			<name>Tina Beauchemin</name>
			<email>tbeauchemin@embios.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
		<p>
	Emerald Bio, the Science and Technology Facilities Council (STFC) and the University of Oxford announce that the parties have entered into a strategic partnership providing Emerald Bio with the exclusive rights to commercialize PiMS technology in the life sciences.&nbsp; Furthermore, the partnership includes additional collaboration and development efforts to continue to provide software innovations to the protein science community.</p>
<p>
	PiMS, the first protein-centric laboratory information management system, is the culmination of seven years of development to create a solution that addresses the complexity of data management unique to molecular biology environments in protein production laboratories.&nbsp; PiMS manages information about targets, constructs, protocols, experiments and samples within the protein production workflow.</p>
<p>
	<a href="/images/uploads/PiMS_Press_Release_Final.pdf">Read the full release</a></p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>SSGCID and CSGID Pioneer Discovery of New Pathogen Protein Structures</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/ssgcid_and_csgid_pioneer_discovery_of_new_pathogen_protein_structures" />
	  <id>tag:,2012:/news/1.627</id>
	  <published>2012-11-19T20:49:00Z</published>
	  <updated>2012-11-27T12:51:02Z</updated>
	  <author>
			<name>Tina Beauchemin</name>
			<email>tbeauchemin@embios.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
			<div class="news_image">
				<img src="http://www.emeraldbiostructures.com/images/blog/SSGCID_CSGID.jpg" alt="" />
				<p class="caption"></p>
			</div>
			
		<p>
	The Seattle Structural Genomics Center for Infectious Disease and the Center for Structural Genomics of Infectious Diseases announced today they will receive up to $52.4 million over five years, from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.&nbsp; For the first year, the centers will receive a total of approximately $9.1 million.&nbsp; The contracts will support the centers&rsquo; continuing research into new drugs, vaccines and diagnostics to combat deadly emerging or re-emerging infectious diseases. The funding is a renewal of NIAID contracts first received by the two centers in 2007, and depending on contract options, could total $52.4 million. The collaboration between the Seattle Structural Genomics Center for Infectious Disease (SSGCID) and the Center for Structural Genomics of Infectious Diseases (CSGID) is aimed at state-of-the-art structural genomics technologies to characterize the three-dimensional structures of proteins from more than 40 bacterial, protozoan and viral pathogens. Among the pathogens studied are those responsible for the plague, anthrax, salmonellosis, cholera, tuberculosis (TB), leprosy, amoebic dysentery and influenza.</p>
<p>
	<a href="/images/uploads/SSGCID_CSGID_Renewal.pdf">Read the full release</a></p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>Emerald Bio and SomaLogic Publish First Structure Demonstrating Molecular Basis of High Affinity of SOMAmer™ Reagents</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/emerald_bio_and_somalogic_publish_first_structure_demonstrating_molecular_b" />
	  <id>tag:,2012:/news/1.624</id>
	  <published>2012-11-08T16:03:40Z</published>
	  <updated>2012-11-16T13:41:42Z</updated>
	  <author>
			<name>Tina Beauchemin</name>
			<email>tbeauchemin@embios.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
			<div class="news_image">
				<img src="http://www.emeraldbiostructures.com/images/blog/SomaLogic.png" alt="" />
				<p class="caption"></p>
			</div>
			
		<p>
	The molecular structure of a SOMAmer&trade; (Slow Off-rate Modified Aptamer) reagent bound to its specific protein has been revealed for the first time by a team of scientists from Emerald Bio and SomaLogic in a manuscript published online today in the Proceedings of the National Academy of Science (PNAS). These structural studies demonstrate the molecular uniqueness of SOMAmer reagents, explain their unparalleled protein binding capabilities, and underline their therapeutic and diagnostic applications. Their analyses demonstrate the molecular basis for the vast improvement in protein binding by SOMAmers as compared to traditional aptamers, emphasizing that SOMAmers represent an entirely new class of molecular &ldquo;affinity reagents&rdquo; with multiple useful applications in life sciences and medicine.<br />
	<br />
	The PNAS article, entitled &ldquo;Unique Motifs and Hydrophobic Interactions Shape the Binding of Modified DNA Ligands to Proteins Targets&rdquo; by D.R. Davies et al., can be found at: <a href="http://www.pnas.org/cgi/doi/10.1073/pnas.1213933109">http://www.pnas.org/cgi/doi/10.1073/pnas.1213933109</a></p>
<p>
	<a href="/images/uploads/SOMAmer_PDGF_press_release_FINAL2_11-5-12.pdf">Read the full release</a></p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>Emerald Bio Structural Biologists Team with Tetra Discovery Partners, Receiving NIH Funding for Alzheimer’s Disease Research</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/emerald_bio_structural_biologists_team_with_tetra_discovery_partners_receiv" />
	  <id>tag:,2012:/news/1.607</id>
	  <published>2012-07-06T15:58:52Z</published>
	  <updated>2012-07-06T12:43:54Z</updated>
	  <author>
			<name>Mary</name>
			<email>mcanady@comprendia.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
			<div class="news_image">
				<img src="http://www.emeraldbiostructures.com/images/blog/Tetra_Logo.jpg" alt="" />
				<p class="caption"></p>
			</div>
			
		<p>
	Emerald Bio is collaborating with <a href="http://www.tetradiscovery.com">Tetra Discovery Partners</a> to enable the discovery of modulators of phosphodiesterase 4 (PDE4) to slow the progression of Alzheimer&rsquo;s disease. As noted in <a href="http://www.prnewswire.com/news-releases/tetra-discovery-partners-receives-major-nih-award-to-develop-new-alzheimers-drug-159553785.html">Tetra&rsquo;s recent press release</a>, the project was recently awarded $1.5 million in direct funding from the National Institutes of Health (NIH) and up to $10 million in total for the five year period. Tetra is one of the first non-academic companies to be awarded funds through the NIH&rsquo;s Blueprint Neurotherapeutics Network (BPN).&nbsp; Emerald&rsquo;s Chief Scientific Officer Alex Burgin is a key member of the research team and Emerald will be providing structural biology services throughout the five year support period. Dr. Burgin is a well recognized expert in the phosphodiesterase field, and was first author on a ground-breaking Nature Biotechnology paper reporting the discovery and co-crystal structure of the <a href="http://www.emeraldbiostructures.com/publications/allosteric_modulators_of_pde_4">first allosteric modulators of PDE4</a>. &ldquo;Our ability to access Emerald&rsquo;s structural biology insights are an important factor in the continued success of Tetra&rsquo;s efforts to find drugs to treat Alzheimer&rsquo;s disease,&rdquo; said Mark Gurney, Tetra&rsquo;s founder and President.</p>
<p>
	<a href="http://www.prnewswire.com/news-releases/tetra-discovery-partners-receives-major-nih-award-to-develop-new-alzheimers-drug-159553785.html">Read the full release</a></p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>Emerald Bio Announces Unprecedented Multi&#45;Target 3D Structural Biology Success</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/emerald_bio_announces_unprecedented_multi_target_3d_structural_biology_succ" />
	  <id>tag:,2012:/news/1.604</id>
	  <published>2012-06-12T14:59:38Z</published>
	  <updated>2012-06-12T10:20:39Z</updated>
	  <author>
			<name>Mary</name>
			<email>mcanady@comprendia.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
		<p>
	<strong>BEDFORD, MA. June 12, 2012.</strong> Emerald Bio announces early delivery of the 500<sup>th</sup> novel protein structure under the Seattle Structural Genomics Center for Infectious Disease (SSGCID), a consortium of researchers from Seattle Biomedical Research Institute (Seattle BioMed), Emerald Bio, the University of Washington and Pacific Northwest National Laboratory (PNNL). Funded by a contract from the National Institute of Allergy and Infectious Diseases (NIAID, within the National Institutes of Health), the collaboration was launched in late 2007 to enable the discovery of new treatments for emerging infectious disease by providing 3D structure insights for hundreds of novel targets.</p>
<p>
	The structures are made available to the drug discovery field through deposition in the NIH-supported protein data bank (PDB). &ldquo;The goal was to deposit at least 375 structures in the PDB within five years, and by applying Emerald&rsquo;s unique multi-target parallel processing crystallography platform we&rsquo;ve been able to exceed expectations and meet that goal early&rdquo; said Dr. Peter Myler, Director of SSGCID and Member at Seattle BioMed.</p>
<p>
	The structures available encompass novel targets from category A to C agents, and in addition to hundreds of bacterial targets, include 79 structures from eukaryotic pathogens, as well as numerous ligand-bound structures. Over the course of the program, the work is supported by 55 publications in peer-reviewed scientific journals.</p>
<p>
	"SSGCID has become one of the world&#39;s most productive structural genomics projects," said Johan Pontin, CEO of Emerald Bio. "The Emerald crystallography team is providing new structures to our collaborators a rate of over two hundred per year."</p>
<p>
	<strong>About Emerald Bio:</strong></p>
<p>
	Emerald Bio is a protein resource company. We leverage our unique assets and know-how in biochemistry and structural biology to further our clients&rsquo; understanding of proteins, and that ultimately leads to improved human health. Emerald Bio is a privately owned company that maintains facilities in Seattle and Boston. Our dedicated team supports leading research institutes and commercial therapeutic and diagnostic companies worldwide. To learn more about Emerald Bio&rsquo;s array of key resources, visit www.embios.com.</p>
<p>
	&nbsp;</p>
<p>
	<strong>ABOUT SEATTLE BIOMEDICAL RESEARCH INSTITUTE:</strong></p>
<p>
	Seattle BioMed is the largest independent, non-profit organization in the U.S. focused solely on infectious disease research. Our research is the foundation for new drugs, vaccines and diagnostics that benefit those who need our help most: the 14 million who will otherwise die each year from infectious diseases, including malaria, HIV/AIDS and tuberculosis. Founded in 1976, Seattle BioMed has more than 360 staff members. By partnering with key collaborators around the globe, we strive to make discoveries that will save lives sooner. For more information, visit www.seattlebiomed.org.</p>
<p>
	&nbsp;</p>
<p>
	<strong>Contacts:</strong></p>
<p>
	For Emerald Bio:</p>
<p>
	Johan Pontin</p>
<p>
	(206) 780-8900</p>
<p>
	&nbsp;</p>
<p>
	For Media:</p>
<p>
	Mary Canady</p>
<p>
	(858) 922-6640</p>
<p>
	mcanady[at]comprendia[dot]com</p>
<div class="skype_pnh_menu_container" id="skype_pnh_menu_container" onmouseout="SkypeClick2Call.MenuInjectionHandler.hideMenu(event)" onmouseover="SkypeClick2Call.MenuInjectionHandler.showMenu(this, event)" style="display:none;">
	<div class="skype_pnh_menu_click2call">
		<a class="skype_pnh_menu_click2call_action" id="skype_pnh_menu_click2call_action">Call</a></div>
	<div class="skype_pnh_menu_click2sms">
		<a class="skype_pnh_menu_click2sms_action" id="skype_pnh_menu_click2sms_action">Send SMS</a></div>
	<div class="skype_pnh_menu_add2skype">
		<a class="skype_pnh_menu_add2skype_text" id="skype_pnh_menu_add2skype_text">Add to Skype</a></div>
	<div class="skype_pnh_menu_toll_info">
		<span class="skype_pnh_menu_toll_callcredit">You&#39;ll need Skype Credit</span><span class="skype_pnh_menu_toll_free">Free via Skype</span></div>
</div>
<p>
	&nbsp;</p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>Gilead Sciences Selects Emerald BioStructures for Crystallization Studies of a Novel Membrane Protein Target</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/gilead_sciences_emerald_biostructures_membrane_protein_drug_discovery" />
	  <id>tag:,2012:/news/1.492</id>
	  <published>2012-01-31T20:31:13Z</published>
	  <updated>2012-04-13T20:42:15Z</updated>
	  <author>
			<name>Mary</name>
			<email>mcanady@comprendia.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
			<div class="news_image">
				<img src="/images/uploads/Gilead.gif" alt="" />
				<p class="caption"></p>
			</div>
			
		<p>
	BAINBRIDGE ISLAND, WA. January 31, 2012. Gilead Sciences, Inc. (Foster City, CA) and Emerald BioStructures, Inc. have launched a collaboration to crystallize a novel integral membrane protein drug target.&nbsp; The structural studies will support Gilead&rsquo;s efforts to use structural insights to support drug discovery for this challenging class of targets.&nbsp; The project will make use of Emerald&rsquo;s high throughput crystallization platform and specialized membrane protein crystallization tool set and includes a technology transfer component.&nbsp;<br />
	&nbsp;<br />
	<strong>About Emerald BioStructures&nbsp;</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />
	Emerald BioStructures is an integrated gene-to-structure contract research organization that provides collaborative drug discovery services to pharmaceutical companies, biotechnology companies, academic institutions, and government facilities. Emerald has extensive expertise in the engineered expression, protein production and crystal structure determination of GPCRs and integral membrane proteins. The company operates a high-throughput platform leveraged for fragment-based lead discovery and structure-based drug design. Emerald&rsquo;s work provides a solid foundation for the discovery of highly selective, efficacious drugs. www.emeraldbiostructures.com</p>
<p>
	<strong>About Gilead Sciences</strong><br />
	Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. Gilead&rsquo;s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.</p>
<p>
	<strong>Emerald BioStructures Contact:</strong><br />
	Emerald BioStructures: Diana Wetmore, VP of Business Development &amp; Alliances (206) 780-8959, <a href="mailto:dwetmore@embios.com">dwetmore@embios.com</a></p>
<p>
	<strong>For Media:</strong><br />
	Mary Canady, Comprendia LLC<br />
	<a href="mailto:mcanady@comprendia.com">mcanady@comprendia.com</a></p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>Heptares Therapeutics and Emerald BioStructures Build Their GPCR Structure Collaboration</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/heptares_therapeutics_and_emerald_biostructures_build_their_gpcr_structure" />
	  <id>tag:,2011:/news/1.480</id>
	  <published>2011-12-06T19:29:51Z</published>
	  <updated>2012-03-05T10:31:53Z</updated>
	  <author>
			<name>Mary</name>
			<email>mcanady@comprendia.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
		<p>
	Heptares Therapeutics and Emerald BioStructures, leaders in G-protein-coupled receptor (GPCR) structural biology, recently expanded their agreement aimed at combining their expertise to enable Heptares&rsquo; discovery of new therapies for this important family of drug targets. GPCRs are the target of 25-30% of all drugs, but have remained recalcitrant to structure based drug discovery due to their association with cell membranes. Heptares and Emerald began working together on these difficult targets in February 2010. In this FTE-based agreement, the two companies will work together using protein engineering, purification studies, and crystallization optimization to aid active GPCR structural studies. Heptares&rsquo; STaRS&reg; GPCR stabilizing technology will be complemented by Emerald&rsquo;s expression platform and depth of experience with the crystallization of membrane proteins.</p>
<p>
	<strong>About Emerald BioStructures&nbsp;</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />
	Emerald BioStructures is an integrated gene-to-structure contract research organization that provides collaborative drug discovery services to pharmaceutical companies, biotechnology companies, academic institutions, and government facilities. The company operates a high-throughput platform leveraged for fragment-based lead discovery, structure-based drug design, and elucidation of antibody-antigen structures. Emerald&rsquo;s work provides a solid foundation for the discovery of highly selective, efficacious drugs. <a href="http://www.emeraldbiostructures.com">www.emeraldbiostructures.com</a></p>
<p>
	<strong>About Heptares</strong><br />
	Heptares is a drug discovery company creating new medicines targeting G-protein-coupled receptors (GPCRs). The company is currently leveraging its GPCR expertise and proprietary StaR&reg; technology to build a pipeline of best-in-class and first-in-class GPCR-targeted medicines for the treatment of CNS, metabolic and other diseases. <a href="http://www.heptares.com">www.heptares.com</a></p>
<p>
	Emerald BioStructures Contact:<br />
	Emerald BioStructures: Diana Wetmore, VP of Business Development &amp; Alliances (206) 780-8959, <a href="mailto:dwetmore@embios.com">dwetmore@embios.com</a></p>
<p>
	&nbsp;</p>
 
	  ]]></content>
	</entry>

	<entry>
	  <title>Emerald BioStructures and UCB Announce Multi&#45;year Extension of Structure&#45;Based Drug Discovery Collaboration for Multiple Targets</title>
	  <link rel="alternate" type="text/html" href="http://www.emeraldbiostructures.com//news/emerald_biostructures_and_ucb_announce_multi_year_extension" />
	  <id>tag:,2011:/news/1.478</id>
	  <published>2011-10-26T12:05:49Z</published>
	  <updated>2012-04-13T20:11:51Z</updated>
	  <author>
			<name>Mary</name>
			<email>mcanady@comprendia.com</email>
				  </author>

	  <content type="html"><![CDATA[
	  	
			<div class="news_image">
				<img src="" alt="" />
				<p class="caption"></p>
			</div>
			
		<p>
	<strong>Emerald to Apply Fragment Screening and Structural Biology Expertise to Support UCB Pipeline</strong></p>
<p>
	BAINBRIDGE ISLAND, Wash.--(BUSINESS WIRE - October 26, 2011)--Emerald BioStructures today announced a three-year extension of its ongoing collaboration with <a href="http://www.ucb.com/">UCB</a>. The strategic aspects of this renewed relationship will provide Emerald with research funding over the three-year period and the opportunity to receive milestones and royalties on future drug product revenues.</p>
<p>
	&ldquo;The collaborative nature of our relationship with the team at Emerald BioStructures has been instrumental in elucidating multiple targets and identifying promising, novel lead compounds in our discovery programs,&rdquo; commented Dr. Ismail Kola, President, UCB NewMedicines.</p>
<p>
	Emerald will apply its high-throughput crystallography and ligand characterization expertise to provide fragment screening and structural biology support for UCB&rsquo;s severe diseases discovery programs. Emerald and UCB first entered into collaboration in February 2009.</p>
<p>
	&ldquo;It is our mission to enable companies like UCB with structural insights,&rdquo; commented Diana Wetmore, VP of Business Development and Alliances at Emerald BioStructures. &ldquo;We are very excited about moving into this new phase with UCB, expanding our role in the discovery of breakthrough medicines for unmet needs.&rdquo;</p>
<p>
	<strong>Meet Emerald BioStructures at BIOEurope in Dusseldorf, Germany &ndash; October 31-November 2</strong></p>
<p>
	Diana Wetmore, VP of Business Development and Alliances at Emerald BioStructures, will be participating in the partnering forum at <a href="http://www.ebdgroup.com/bioeurope/index.php">BIOEurope in Dusseldorf, Germany</a> and is available for select one-on-one meetings with interested parties.</p>
<p>
	About UCB</p>
<p>
	UCB, Brussels, Belgium (<a href="http://www.ucb.com">http://www.ucb.com</a>) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).</p>
<p>
	About Emerald BioStructures</p>
<p>
	Emerald BioStructures is an integrated gene-to-structure contract research organization that provides collaborative drug discovery services to pharmaceutical companies, biotechnology companies, academic institutions, and government facilities. The company operates a high-throughput platform leveraged for fragment-based lead discovery, structure-based drug design, and elucidation of antibody-antigen structures. Emerald&rsquo;s work provides a solid foundation for the discovery of highly selective, efficacious drugs. <a href="http://www.emeraldbiostructures.com">http://www.emeraldbiostructures.com</a></p>
<p>
	Contacts</p>
<p>
	For Emerald BioStructures:<br />
	Diana Wetmore, 206-780-8959<br />
	or<br />
	For Media:<br />
	MacDougall Biomedical Communications<br />
	Jennifer Conrad, 781-235-3060</p>
 
	  ]]></content>
	</entry>


</feed>